🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

This 👇is an important survey from Y-ECCO Do contribute

Real world data on the effectiveness of #risankizumab in refractory #Crohn's disease. Access the paper here: bit.ly/4eac0Zo Benjamin Zare Beatriz Gros Charlie Lees Mark Samaan and colleagues. BSG BSG Trainees Phil Smith Gio McGinty Vivek Goodoory

Real world data on the effectiveness of #risankizumab in refractory #Crohn's disease. Access the paper here: bit.ly/4eac0Zo Benjamin Zare Beatriz Gros Charlie Lees Mark Samaan and colleagues. BSG BSG Trainees Phil Smith Gio McGinty Vivek Goodoory

Real world data on the effectiveness of #risankizumab in refractory #Crohn's disease. Access the paper here: bit.ly/4eac0Zo Benjamin Zare Beatriz Gros Charlie Lees Mark Samaan and colleagues. BSG BSG Trainees Phil Smith Gio McGinty Vivek Goodoory

Risankizumab in refractory #CD patients N=53 👫51% B2 & 17% B3 behavior Perianal dis 47% Prior bowel 🔪 79% All had failed at least to 1 antiTNF (>90% to two) + VDZ + UST (and some received off label TOFA) ✅75% persisted at w52 Dont miss out our latest publication

🔴 Effectiveness of #risankizumab induction and maintenance #therapy for refractory #Crohn’s #disease 📘 Frontline Gastro 🔵 👉tinyurl.com/yfhs544d 🟣 Y-ECCO Charlie Lees Seb Daniela Guerrero Vinsard MD Maria Chaparro Top Biomedical Science David T. Rubin, MD #GITwitter

🎧 Have you heard? You can listen back to all of the #FGpodcast episodes at fgbmj.podbean.com (or on your favourite podcast app!) Gio McGinty Vivek Goodoory Rex Wan-Hin Hui Philip Dunne James Kennedy Oliver Tavabie Aditi Kumar Phil Smith

Our podcast with Frontline Gastro and Aditi Kumar discussing our paper on risankizumab in refractory Crohn’s disease just dropped. Tune in to hear the exciting results! Always great working with Mark Samaan Charlie Lees Beatriz Gros

Really enjoyed this, especially the points from Mark Samaan about the importance of real world studies as part of the evidence base - more patient centred outcomes, including subgroups excluded from RCTs, clues to sequencing and positioning Rx in biorefractory cohorts

James Kennedy Mark Samaan Agree excellent podcast Aditi Kumar Frontline Gastro positioning real world data with Risankizumab in treatment refractory Crohn’s disease alongside the gold standard of randomised controlled trials. Benjamin Zare Mark Samaan Beatriz Gros Charlie Lees

Fantastic podcast with Mark Samaan and Benjamin zare on their real- world study on risankizumab- listen below! Frontline Gastro

Look forward to listening to this on my commute tomorrow especially in light of the glowing reviews!

The latest #FGpodcast is out...and it's a must-listen! Aditi Kumar dives deep into out recent paper on the real-world experience of risankizumab for refractory Crohn’s disease with authors Mark Samaan and @zarebenjamin. Available wherever you get your podcasts: ▶️ Apple:

Thank you to Dr Karen Kemp, Mark Samaan, 𝗗𝗿 𝗔𝗷𝗮𝘆 𝗠 𝗩𝗲𝗿𝗺𝗮, & Alan Lobo for their work on applying STRIDE-II principles to UK #Crohns care. A step forward for individualized #IBD management!

Two #IBD patients. One on medication, one not. Both in remission. But with different routes to that same destination. Welcome to "Wrestling the Octopus", a new 8-part podcast series from Nigel H 🎸🎸🎸🎸🥁 and me. 🎧 Episode 1 is now on the decks! open.spotify.com/episode/06rHme…

Excited to announce results of our #ADDapt trial After 6 years and the help of 154 people with #CrohnsDisease we prove that restricting #emulsifiers improves disease Award winning presentation from Aaron Bancil at #ECCO25 Excited for next steps to help people with Crohns

The Skyrizi's the limit for Crohn’s treatment! 🌥️ This real-world study in Frontline Gastro by Benjamin Zare Mark Samaan shows risankizumab’s promise in treating Crohn’s disease, with 52% of patients achieving clinical remission by week 52. 💪📉 Brush up on this relatively new

Development and external validation of an endoscopic and histologic pouchitis assessment tool: the Atlantic Pouchitis Index Congrats to ⁦Rocio Sedano MD⁩ for leading this over the last 5 years and to all collaborators for their guidance and input. pubmed.ncbi.nlm.nih.gov/40675404/